3 Bioscience Park Dr.
About Codagenix, Inc.
Codagenix is a clinical stage, venture and public-sector-funded small business that is using our synthetic biology-based vaccine design platform “SAVE” to construct prophylactic viral vaccines and oncolytic agents. All viruses, whether Zika or influenza, uses the host cell ribosome to translate their genome and synthesize their proteins. SAVE is a computer algorithm that re-codes and “de-optimizes” viral genes – in turn putting the wild-type viral genes in a “language” read slowly by the mammalian host ribosome. De-optimization results in a vast reduction of pathogenesis, yet induction of a potent immune response given the presentation of ALL, perfectly matched antigens of the target. This platform has universal applications to the re-design of viral genomes.
Codagenix’s lead program is a live-attenuated, universal Influenza vaccine that has demonstrated safety and broad immunogenicity in a Phase I clinical trial. Using SAVE, Codagenix is developing a pipeline of live-attenuated vaccines against other targets including: RSV (Phase I Q1-2019), Zika (Phase I Q1-2019), and Dengue as well as rationally designed oncolytic candidates against Melanoma, Triple-Negative Breast Cancer, and Neuroblastoma.
Codagenix also has an established partnership in the agricultural space - designing and co-developing SAVE-deoptimized vaccines for swine, canine, bovine, and other markets.
35 articles with Codagenix, Inc.
Codagenix Announces Appointment of Kimber Poffenberger, Ph.D., as Chief Strategy Officer
Codagenix Inc. today announced that Kimber Poffenberger, Ph.D., has been appointed Chief Strategy Officer.
As biopharma executives sought funding last week at the BIO CEO & Investor Conference, the strategic mindset could be summed up in three words: flexibility, creativity and concession.
Codagenix Announces Close of $25 million Extension of Series B
Codagenix Inc. today announced the completion of a $25 million Series B extension financing, with participation from a new investor, the Serum Institute of India Pvt. Ltd., along with existing investors Euclidean Capital and Adjuvant Capital.
Codagenix Announces Appointment of Paul Grint, MD, as Executive Chairman of its Board of Directors
Codagenix Inc. announced that Paul Grint, MD, has been appointed Chairman of the Board of Directors.
Codagenix Receives FDA Fast Track Designation for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax™-RSV
Codagenix Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CodaVax™-RSV, an intranasal, live-attenuated vaccine candidate, for the prevention of respiratory syncytial virus (RSV).
Codagenix Initiates Dosing in Phase 3 Efficacy Trial of Intranasal COVID-19 Vaccine as Part of WHO-Sponsored Solidarity Trial Vaccines
Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, in collaboration with the Serum Institute of India Pvt. Ltd., today announced dosing has been initiated in an international, multi-center, randomized placebo-controlled Phase 3 clinical trial of CoviLiv.
Codagenix Announces Award with the US Department of Defense for Development of Balanced, Tetravalent Dengue Vaccine
Codagenix Inc. today announced the Department of Defense has granted the company a $4.4 million award to progress development of CodaVax-DENV, its next-generation tetravalent dengue vaccine candidate.
SARS-CoV-2 typically enters the body via the nose or mouth. Because of this, many think a nasal spray vaccine would do a better job of preventing COVID-19 infection and cutting transmission than an injection.
Codagenix Completes Dosing in Phase 1 Trial of Universal Influenza Vaccine
Codagenix Inc. today announced that it has completed dosing of its Phase 1 clinical trial to evaluate CodaVax™-H1N1, a universal, live-attenuated influenza vaccine.
Codagenix Leadership to Present at the 2022 Jefferies Healthcare Conference
Codagenix, Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, today announced that company leadership will present at the upcoming 2022 Jefferies Healthcare Conference, taking place in New York City, June 8-10, 2022.
Codagenix Receives FDA Clearance of Investigational New Drug Application for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax™-RSV
Codagenix Receives FDA Clearance of Investigational New Drug Application for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax™-RSV.
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
Codagenix Initiates Phase 1 Evaluation of Intranasal Vaccine CoviLiv™ for Use as COVID-19 Booster
Codagenix Inc. today announced the first patient has been dosed in a U.K.-based Phase 1 clinical trial to evaluate the use of Codagenix's novel intranasal, live-attenuated virus vaccine, CoviLiv™, as a booster in healthy adults following prior vaccination with approved COVID-19 vaccines.
Codagenix Intranasal COVID-19 Vaccine Shows Potent Cellular Immune Response Against Conserved Viral Proteins, Indicating Potential for Immunogenicity Against Omicron and Future Variants in Phase 1 Data
Codagenix Inc. today announced interim Phase 1 data indicating induction of T cell immunity against highly-conserved antigens of the SARS-CoV-2 Omicron variant following two doses of its intranasal vaccine, CoviLiv (previously called Covi-Vac).
Codagenix is entering the vaccine arena with a possible new frontrunner in protection: CoviLiv. It's an intranasal COVID vaccine that provides hope against subvariants.
BioSpace Movers & Shakers, Jan. 14
1/14/2022Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Codagenix Welcomes Bruce Taillon as Executive Vice President of Animal Health
Codagenix, Inc. today announced the appointment of Bruce E. Taillon, Ph.D., as Executive Vice President of Animal Health.
Codagenix to Present Promising Preclinical Data for Oncolytic Virus Therapeutic CodaLytic™ at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Codagenix, Inc., a clinical-stage synthetic biology company pioneering a novel platform for vaccines and oncolytic virus therapies, today announced they will present data indicating preclinical efficacy of CodaLytic™, its first rationally attenuated oncolytic virus immunotherapy, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting.
Codagenix Announces Appointment of Two New Members to its Board of Directors
Codagenix, Inc. this week announced the appointment of two new members to its Board of Directors each with significant biotechnology and life sciences experience, Lori Rudolph-Owen , Ph.D., and Jill Howe .
Codagenix Presents Positive Phase 1 Data for COVI-VAC Intranasal COVID-19 Vaccine at IDWeek 2021
Codagenix, Inc., a clinical-stage biotechnology company pioneering a novel platform for vaccines and oncolytic virus therapies, today presented data from ongoing studies of their novel intranasal COVID-19 vaccine, COVI-VAC, at the IDWeek 2021 annual conference held virtually September 29-October 3.